1. Introduction {#sec1-molecules-24-04521}
===============

The modern paradigm in drug discovery is based on two major traits. The first includes mimicking the three-dimensional structure of the targeted protein receptor by incorporation of tailor-made amino acids (AAs) \[[@B1-molecules-24-04521],[@B2-molecules-24-04521],[@B3-molecules-24-04521],[@B4-molecules-24-04521],[@B5-molecules-24-04521],[@B6-molecules-24-04521],[@B7-molecules-24-04521],[@B8-molecules-24-04521]\]. The second is to increase the metabolic stability of a drug molecule by the strategic fluorine for hydrogen substitution \[[@B9-molecules-24-04521],[@B10-molecules-24-04521],[@B11-molecules-24-04521],[@B12-molecules-24-04521],[@B13-molecules-24-04521]\]. Obviously, the presence of a tailor-made AA's backbone and fluorinated residues provide an additional host of subtle useful properties, allowing fine-tuning of the desired bio-activity and pharmacokinetics \[[@B14-molecules-24-04521],[@B15-molecules-24-04521]\]. In this line of structural inquiry, fluorinated AAs, including α- \[[@B16-molecules-24-04521],[@B17-molecules-24-04521],[@B18-molecules-24-04521],[@B19-molecules-24-04521],[@B20-molecules-24-04521],[@B21-molecules-24-04521],[@B22-molecules-24-04521],[@B23-molecules-24-04521],[@B24-molecules-24-04521]\] and β-derivatives \[[@B25-molecules-24-04521],[@B26-molecules-24-04521],[@B27-molecules-24-04521]\], are considered of distinct potential in the modern drug design \[[@B28-molecules-24-04521]\]. Synthesis and biological applications of fluorinated tailor-made AAs reported before 1994 are comprehensively covered by the book \[[@B29-molecules-24-04521]\]. More recent data on the remarkable progress made in this area of research can be found in the reviews \[[@B16-molecules-24-04521],[@B17-molecules-24-04521],[@B18-molecules-24-04521],[@B19-molecules-24-04521],[@B20-molecules-24-04521],[@B21-molecules-24-04521],[@B22-molecules-24-04521],[@B23-molecules-24-04521],[@B24-molecules-24-04521],[@B25-molecules-24-04521],[@B26-molecules-24-04521],[@B27-molecules-24-04521]\] and the current publications \[[@B30-molecules-24-04521],[@B31-molecules-24-04521],[@B32-molecules-24-04521],[@B33-molecules-24-04521],[@B34-molecules-24-04521],[@B35-molecules-24-04521],[@B36-molecules-24-04521],[@B37-molecules-24-04521],[@B38-molecules-24-04521],[@B39-molecules-24-04521],[@B40-molecules-24-04521],[@B41-molecules-24-04521],[@B42-molecules-24-04521],[@B43-molecules-24-04521],[@B44-molecules-24-04521],[@B45-molecules-24-04521],[@B46-molecules-24-04521],[@B47-molecules-24-04521],[@B48-molecules-24-04521],[@B49-molecules-24-04521],[@B50-molecules-24-04521],[@B51-molecules-24-04521]\]. Synthesis of fluorinated AAs is part of a more general field of asymmetric synthesis of tailor-made amino acids. Therefore, some recent advances, covered by the excellent review articles, should be mentioned \[[@B52-molecules-24-04521],[@B53-molecules-24-04521],[@B54-molecules-24-04521],[@B55-molecules-24-04521],[@B56-molecules-24-04521],[@B57-molecules-24-04521],[@B58-molecules-24-04521],[@B59-molecules-24-04521],[@B60-molecules-24-04521],[@B61-molecules-24-04521]\].

One of the most rapidly growing areas in the modern drug design is the application of fluorinated residues as bioisosteres of naturally occurring moieties \[[@B28-molecules-24-04521]\]. In particular, based on considerations of the biologically relevant size, as cumulatively defined by van der Waals volume (vdW), A values, Taft Es values, and biphenyl interference values \[[@B62-molecules-24-04521],[@B63-molecules-24-04521],[@B64-molecules-24-04521],[@B65-molecules-24-04521],[@B66-molecules-24-04521]\], trifluoromethyl group has often been considered to be isosteric with an iso-propyl substituent. Although a CF~3~ and *i*-Pr are clearly of a different shape, they are sterically much closer related than to Me, Et, or *t*-Bu groups. As presented in [Figure 1](#molecules-24-04521-f001){ref-type="fig"}, the differences projected by several biphenyl rotational values are relatively modest, suggesting steric mimicry between these two groups, though the effective functional mimicry is very much dependent upon the actual biochemical settings \[[@B67-molecules-24-04521]\]. In this context, the bioisosteric relationships between CF~3~ and *i*-Pr can be used for 2-amino-4,4,4-trifluorobutanoic acid **1** \[[@B68-molecules-24-04521],[@B69-molecules-24-04521],[@B70-molecules-24-04521],[@B71-molecules-24-04521],[@B72-molecules-24-04521],[@B73-molecules-24-04521],[@B74-molecules-24-04521],[@B75-molecules-24-04521],[@B76-molecules-24-04521]\] substitution for leucine **2** in the de novo design of biologically active peptides and peptidomimetics \[[@B77-molecules-24-04521],[@B78-molecules-24-04521],[@B79-molecules-24-04521],[@B80-molecules-24-04521],[@B81-molecules-24-04521],[@B82-molecules-24-04521],[@B83-molecules-24-04521]\].

As part of our ongoing research program focused on the application of fluorinated tailor-made AAs in pharmaceutical discovery, we needed a convenient access to large quantities of Fmoc-2-amino-4,4,4-trifluorobutanoic acid **1** in both enantiomeric forms. Here, we disclose synthetic procedures specifically developed for large-scale preparation of the (*S*)-*N*-Fmoc-2-amino-4,4,4-trifluorobutanoic acid. The procedure was reliably reproduced several times for consecutive preparation of over 300 g of the target derivative of tailor-made AAs **1**.

2. Results and Discussion {#sec2-molecules-24-04521}
=========================

Our interest in the structural types of tailor-made AAs includes phosphonic analogs \[[@B84-molecules-24-04521],[@B85-molecules-24-04521],[@B86-molecules-24-04521]\], sterically constrained \[[@B87-molecules-24-04521],[@B88-molecules-24-04521]\] and fluorine-containing AAs \[[@B89-molecules-24-04521],[@B90-molecules-24-04521],[@B91-molecules-24-04521]\], all of which are of increasing importance in modern drug design \[[@B2-molecules-24-04521],[@B3-molecules-24-04521],[@B4-molecules-24-04521],[@B5-molecules-24-04521],[@B6-molecules-24-04521],[@B7-molecules-24-04521],[@B8-molecules-24-04521]\]. Moreover, we carefully study nonlinear chiroptical phenomena, such as self-disproportionation of enantiomers \[[@B92-molecules-24-04521],[@B93-molecules-24-04521],[@B94-molecules-24-04521]\] and its manifestation in the properties of AAs \[[@B95-molecules-24-04521],[@B96-molecules-24-04521]\] and chiral marketed pharmaceuticals \[[@B97-molecules-24-04521],[@B98-molecules-24-04521]\]. In the context of synthetic methodology, the chemistry of Ni(II) complexes of AA Schiff bases ([Scheme 1](#molecules-24-04521-sch001){ref-type="scheme"}) \[[@B99-molecules-24-04521],[@B100-molecules-24-04521],[@B101-molecules-24-04521],[@B102-molecules-24-04521]\] has emerged as a dominant, most commonly used approach for asymmetric synthesis of tailor-made AAs. Using the modular approach for the design of chiral Ni(II) complexes of glycine Schiff bases \[[@B103-molecules-24-04521],[@B104-molecules-24-04521]\], the recent research activity has been focusing around four structural types of chiral nucleophilic glycine equivalents **3**--**6** possessing elements of axial **3** \[[@B105-molecules-24-04521]\], both axial and central **4** \[[@B106-molecules-24-04521],[@B107-molecules-24-04521]\] chirality, carbon and nitrogen stereogenic centers **5** \[[@B108-molecules-24-04521],[@B109-molecules-24-04521],[@B110-molecules-24-04521]\], and a proline-derived complex **6** bearing electron-deficient benzyl moiety \[[@B111-molecules-24-04521],[@B112-molecules-24-04521]\]. The Ni(II) complex methodology can be used for direct dynamic kinetic resolution of racemic α- \[[@B113-molecules-24-04521],[@B114-molecules-24-04521],[@B115-molecules-24-04521]\] and β-AAs \[[@B116-molecules-24-04521]\], provided that the corresponding racemic AAs are readily commercially available. More general application of this chemistry is based on homologation of the glycine moiety 7 via, for example, alkylations \[[@B117-molecules-24-04521],[@B118-molecules-24-04521]\], aldol \[[@B119-molecules-24-04521],[@B120-molecules-24-04521]\], Mannich \[[@B121-molecules-24-04521],[@B122-molecules-24-04521]\], and Michael \[[@B123-molecules-24-04521],[@B124-molecules-24-04521],[@B125-molecules-24-04521]\] addition reactions. Multi-step transformations can also be realized, as demonstrated by efficient synthesis of (1*R*,2*S*)-1-amino-2-vinylcyclopropanecarboxylic acid \[[@B126-molecules-24-04521],[@B127-molecules-24-04521]\]. Derivatives **8** are conveniently disassembled to release the target AAs **9**, along with recycling of the corresponding chiral ligands, rendering the process commercially attractive.

Chemical properties and particularities of the homologation of glycine Schiff base complexes **3**--**6** are still under investigation, but proline-derived (*S*)-**6** showed some advantageous reactivity and stereochemical outcome under alkyl halide alkylation conditions. Based on the previous data \[[@B68-molecules-24-04521]\], we decided to use complex (*S*)-**6** for the large-scale asymmetric synthesis of 2-amino-4,4,4-trifluorobutanoic acid **1**.

*Alkylation of (S)-**6** with ICH~2~CF~3~.* The alkylation of chiral glycine equivalent (*S*)-**6** with trifluoroethyl iodide is presented in [Scheme 2](#molecules-24-04521-sch002){ref-type="scheme"}. The development of a commercially viable, large-scale synthetic process is significantly more challenging as compared with a methodological investigation. Thus, besides the standard variables such as chemical yield and stereochemical outcome, special attention must be paid to operational convenience and overall cost structure. To optimize the alkylation step, we meticulously evaluated series of reaction solvents, bases, and stoichiometry of the reaction. For example, among the solvents promising results were obtained in DMSO, CH~3~CN, and DMF. The latter was eventually selected as the optimal solvent. Among the bases, we assessed KOH, NaOH, NaOMe, KOMe, KOH/MeOH, and NaOH/MeOH in various commercially available concentrations and combinations. As a result, solution of KOH in methanol was determined to be the optimal base.

Normally, alkylation of glycine Schiff bases complexes with proline-derived ligands of type **6** is conducted in the presence of a large excess of a base, usually 5--10 equivalents \[[@B128-molecules-24-04521]\]. Therefore, it was an important discovery that for large-scale synthesis, the optimized conditions required only insignificant 5 mol% excess of the base. The same unexpected stoichiometry was found to be optimal for the alkylating reagent. Thus, only 5 mol% excess of the trifluoroethyl iodide was sufficient to achieve optimal yield and the stereochemical outcome.

As shown in [Scheme 2](#molecules-24-04521-sch002){ref-type="scheme"}, possible byproducts in this reactions include minor diastereomer (*S*)(2*R*)-**7** and bis-alkylated product (*S*)-**8**, which are typical impurities in the alkylation reactions of glycine Ni(II) complexes \[[@B129-molecules-24-04521]\]. Other byproducts, such as binuclear complex (*S*)(*S*)-**9** and 4-phenylquinazoline (*S*)-**10**, are the results of oxidative degradation of starting (*S*)-**6** under the action of strong base in the presence of molecular oxygen \[[@B130-molecules-24-04521],[@B131-molecules-24-04521]\]. These byproducts can be effectively eliminated by conducting the alkylation procedure under inert atmosphere. In the present case the reaction was conducted under N~2~.

Another important discovery made in this work was the two-step quenching of the reaction mixture, allowing the precipitation the diastereomerically pure alkylation product (*S*)(2*S*)-**7**. Thus, despite the fact that alkylation of glycine complex (*S*)-**6** takes place with very high diastereoselectivity, usually \>97% de, purification of the major diastereomer to diastereomerically pure state can be expensive in terms of time and silica gel and solvents. Therefore, for a large-scale synthesis, it was unquestionably needed to find a convenient and efficient procedure for isolation of the major diastereomer with maximum chemical yield. After extensive experimentation, we found that quenching the reaction mixture with calculated amount of water in specific sequence allows to solve this critical problem. In particular, the reaction mixture was first treated with water 3-times the amount of solvent DMF, allowing the mixture to be stirred at 20\~40 °C for 1 h. This was followed by the second addition of water 2-times the original amount of DMF and stirring for 1 h at the same temperature. This treatment gave rise to the precipitation of major diastereomer (*S*)(2*S*)-**7** of greater than 99% de. Summary of the optimized conditions for the alkylation of (*S*)-**6** with ICH~2~CF~3~ is presented in [Table 1](#molecules-24-04521-t001){ref-type="table"}.

As one can see from the [Table 1](#molecules-24-04521-t001){ref-type="table"}, a quite acceptable chemical yield of alkylation product (*S*)(2*S*)-**7** (\~80%) was obtained using essentially stoichiometric amounts of the reagents. Most importantly, the two-step quenching procedure allowed precipitation of virtually chemically and diastereomerically pure target product (*S*)(2*S*)-**7**. Minor diastereomer (*S*)(2*R*)-**7** and byproducts **8**--**10** could be detected in the aqueous washings but in concentrations below 1%. Some amounts (\~5%) of target (*S*)(2*S*)-**7** were also detected in the aqueous phase, but their recovery deemed economically inefficient. Of particular importance was the confirmation of excellent reproducibility of this process. As presented in [Table 1](#molecules-24-04521-t001){ref-type="table"}, the reaction was performed on 80 g scale (entry 1), and two times on 250 g scale (entries 2 and 3). In all cases, the chemical yield and stereochemical outcome were essentially the same, underscoring the reliability and practicality of this newly developed large-scale process.

Disassembly of major diastereomer (*S*)(2*S*)-**7** and preparation of (*S*)-**12**. The procedure for disassembly of diastereomerically pure (*S*)(2*S*)-**7**, synthesis of (*S*)-**12** and the recovery of chiral ligand (*S*)-**11** is presented in [Scheme 3](#molecules-24-04521-sch003){ref-type="scheme"}.

Generally, the disassembly of Ni(II) complexes of this type is conducted in methanol under the action of 3N hydrochloric acid \[[@B99-molecules-24-04521],[@B100-molecules-24-04521],[@B101-molecules-24-04521],[@B102-molecules-24-04521]\]. However, under these conditions, some amounts of the corresponding methyl esters are being formed leading to some complications in isolation of the target products and lower chemical yields. For the present large-scale synthesis, we decided to use dimethoxyethane (DME), which is a rather chemically inert, low-cost industrial solvent. Another novelty in the present procedure was the use of 6N HCl, allowing to reduce the reaction time. Thus, heating the mixture of (*S*)(2*S*)-**7** and 6N HCl in DME at 50 °C for about 1 h resulted in evident color change form a bright-red to a green, indicating disassembly of the Ni(II) complex (bright-red) and formation of NiCl~2~ (green). The mixture was quenched with calculated amount of water, allowing precipitating hydrochloric salt of chiral ligand (*S*)-**11**. Recovery and reuse of the chiral ligand are usually more than 90%. The first crop of crystals (80%) is always \>98% purity and can be reused without purification; the second crop (\~20%) is \~95% pure and should be recrystallized again for reuse. Overall yield of the reclaimed ligand is usually \~95% and of \>98% purity. Since the structure of the ligand is not changed, it can be reused indefinitely. Again, the loss is about 5% per cycle. The most expensive component of the whole procedure, simply by filtration, is the most practically attractive feature of this method, rendering the process commercially competitive.

The filtrate, containing hydrochloric salt of amino acid (*S*)-**1** and NiCl~2~, was treated with ethylenediaminetetraacetic acid (EDTA) to chelate the Ni(II) ions, followed by the reaction with Fmoc-OSu under usual Fmoc-protection conditions. Target product (*S*)-**12** was isolated by precipitation with toluene form EtOAc solution. As presented in [Table 2](#molecules-24-04521-t002){ref-type="table"}, this procedure was tested first on 10 g scale (entry 1) of compound (*S*)(2*S*)-**7** disassembly, and then successfully reproduced on large, 220 g scale. The obtained chemical yields of 75--80% are quite acceptable for a multi-step procedure, with the final product being collected simply by filtration.

3. Materials and Methods {#sec3-molecules-24-04521}
========================

3.1. General Methods {#sec3dot1-molecules-24-04521}
--------------------

All reagents and solvents were used as received. Reactions were monitored by thin layer chromatography on Merck silica gel 60-F~254~-coated 0.25 mm plates, detected by UV. Flash chromatography was performed with the indicated solvents on silica gel (particle size 0.064--0.210 mm). Yields reported are for isolated, spectroscopically pure compounds. HPLC was performed on a SHIMADZU LC-2010CHT chromatography system (Kyoto, Japan) and a CLASS-VPTM analysis data system (Kyoto, Japan). ^1^H-NMR spectra were recorded on Brüker AVANCE III-400 spectrometer (Biospin, Switzerland).

3.2. Alkylation of (S)-***6*** with ICH~2~CF~3~ {#sec3dot2-molecules-24-04521}
-----------------------------------------------

### 3.2.1. 80 g Scale Reaction {#sec3dot2dot1-molecules-24-04521}

To a 2000 mL four-necked flask was added *N*,*N*-dimethyl-formamide (DMF) (720 mL) under nitrogen atmosphere. Stirring was continued for 30 min with nitrogen flow. Then, the Ni--glycine complex (*S*)-**6** (80.0 g, 1.0 eq.) together with DMF (20 mL), 1,1,1-trifluoro-2-iodoethane (29.32 g, 1.05 eq.) together with DMF (20 mL), and KOH (8.14 g, 1.05 eq.) in MeOH (72 mL) were added to the flask. The mixture was stirred at 20\~35 °C under a nitrogen atmosphere for 1 h. After that, H~2~O (240 mL, 3 v vs. glycine complex (*S*)-**6**) was added into the mixture and stirred for 1 h at 20\~35 °C and precipitate was formed gradually. Then, H~2~O (160 mL, 2 v vs. glycine complex (*S*)-**6**) was added and stirred at the same temperature for 1.5 h. The precipitate was filtered and washed with H~2~O (160 mL, 2 v vs. glycine complex (*S*)-**6**), then dried by air for 18 h to give the product (*S*)(2*S*)-**7** (73.7 g, 81.1% yield, \>99% de).

### 3.2.2. 250 g Scale Reaction {#sec3dot2dot2-molecules-24-04521}

To a 5000 mL four-necked flask, was added *N*,*N*-dimethyl-formamide (DMF) (2250 mL) under nitrogen atmosphere. Stirring was continued for 50 min with nitrogen flow. Then, the Ni--glycine complex (*S*)-**6** (250.0 g, 1.0 eq.) together with DMF (100 mL), 1,1,1-trifluoro-2-iodoethane (91.61 g, 1.05 eq.) together with DMF (50 mL), and KOH (25.42 g, 1.05 eq.) in MeOH (225 mL) together with DMF (100 mL) were added to the flask. The mixture was stirred at 20\~35 °C under a nitrogen atmosphere for 1 h. After that, H~2~O (750 mL, 3 v vs. glycine complex (*S*)-**6**) was added into the mixture and stirred for 1 h at 20\~40 °C and precipitate was formed gradually. Then, H~2~O (500 mL, 2 v vs. glycine complex (*S*)-**6**) was added and stirred at the same temperature for 1 h. The precipitate was filtered and washed with H~2~O (500 mL, 2 v vs. glycine complex (*S*)-**6**), then dried by air for 19.5 h to give the product (*S*)(2*S*)-**7** (228.50 g, 80.4% yield, 97.2 area%, \>99% de).

3.3. Disassembly of Major Diastereomer (S)(2S)-***7*** and Preparation of (S)-***12*** {#sec3dot3-molecules-24-04521}
--------------------------------------------------------------------------------------

To a 2000 mL four-necked flask was added dimethoxyethane (DME) (400 mL), Ni complex (*S*,2*S*)-**7** (220 g, 1.0 eq.) together with DME (30 mL) and HCl (6N, 268 mL, 5.0 eq.) together with DME (10 mL). The mixture was heated to 40\~50 °C and stirred at this temperature for 1 h. After that, the solution was changed to a green suspension and was cooled to 20\~40 °C. H~2~O (440 mL, 2 v) was added and the mixture was stirred at 20\~40 °C for 1.5 h. The precipitate was filtered and washed with DME (88 mL, 0.4 v), 6N HCl (59 mL, 0.27 v), H~2~O (293 mL, 1.33 v), then H~2~O (220 mL, 1 v). The green filtrate was collected to give a solution of (*S*)-**1** (ca. 1500 mL).

To a 3000 mL 4-necked flask containing the above green filtrate was added ethylenediaminetetraacetic acid disodium salt hydrate (122.2 g, 1.02 eq.). With stirring, 48% NaOH (138 g, 5.2 eq.), Na~2~CO~3~ (1.3 eq., 44.35 g), Fmoc-OSu (1 eq., 108.57 g), and acetonitrile (200 mL, 4 v) were added. The resulted mixture was stirred at room temperature for 4 h and acetonitrile was removed. Then, EtOAc (180 mL) and 6N HCl (70 mL, 4 eq.) was added and the phases were separated. The water layer was extracted with ethyl acetate (100 mL), and the combined organic layer was washed with water (100 mL). The combined organic solution was dried with Na~2~SO~4~ (30 g), and then the filtrate was concentrated to 400 mL. The resulted solution was heated to 50\~60 °C, and toluene (400 mL) was added. After that, it was concentrated until 400 mL, and EtOAc (100 mL) was added. Finally, toluene (400 mL) was added and then the solution was concentrated, followed by addition of additional toluene (400 mL) until 800 mL with stirring slowly at 20\~35 °C. The precipitate was filtered, washed with toluene (160 mL), and dried in vacuo at 50 °C for 19 h to afford (*S*)-**12** (99.5 g, 81.5% yield 98.4% ee, a white powder).

^1^H-NMR (400 MHz, CD~3~OD): δ = 7.78 (d, *J* = 7.7 Hz, 2H), 7.69 (d, *J* = 7.7 Hz, 2H), 7.34−7.41 (m, 2H), 7.25−7.33 (m, 2H), 4.42−4.53 (m, 1H), 4.29−4.37 (m, 2H), 4.20−4.29 (m, 1H), 2.78−2.91 (m, 1H), 2.60−2.72 (m, 1H) (see [Supplementary Materials](#app1-molecules-24-04521){ref-type="app"}).

4. Conclusions {#sec4-molecules-24-04521}
==============

The data disclosed in this paper demonstrate that alkylation of Ni(II) complex of glycine Schiff base with CF~3~--CH~2~--I can be successfully conducted on a scale of over 200 g of the corresponding complex, providing a reliable assess to enantiomerically pure (\>99% ee) derivatives of (*S*)-2-amino-4,4,4-trifluorobutanoic acid. The developed method features recyclable chiral auxiliary and optimized operationally convenient conditions, rendering the reported procedure inexpensive and commercially viable. The broader importance of these results is a convincing evidence that the Ni(II) complexes methodology has a degree of practicality, deserving more detailed investigation for large-scale asymmetric synthesis of various pharmacologically valuable tailor-made amino acids.
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![Bioisosteric relationships between CF~3~ and *i*-Pr groups in the context of 2-amino-4,4,4-trifluorobutanoic acid **1** substitution for leucine **2** in the drug design.](molecules-24-04521-g001){#molecules-24-04521-f001}

![Four major types of chiral nucleophilic glycine equivalents **3**--**6** and their homologation to the target enantiomerically pure amino acids (AAs) **9** (carbon center with "\*" means this is a carbon center).](molecules-24-04521-sch001){#molecules-24-04521-sch001}

![Alkylation of (*S*)-**6** with ICH~2~CF~3~; major diastereomer (*S*)(2*S*)-**7** and expected byproducts (*S*)(2*R*)-**7**, (*S*)-**8**, (*S*)-**9**, and (*S*)-**10**.](molecules-24-04521-sch002){#molecules-24-04521-sch002}

![Disassembly of (*S*)(2*S*)-**7**, reclaiming chiral ligand (*S*)-**11**, and preparation of target AAs derivative (*S*)-**12**.](molecules-24-04521-sch003){#molecules-24-04521-sch003}

molecules-24-04521-t001_Table 1

###### 

Optimized conditions for the alkylation step and reproducibility of the method.

  -----------------------------------------------------------------------------------------------------------------------------------------------------
  Entry   Scale          Conditions                                                              Results
  ------- -------------- ----------------------------------------------------------------------- ------------------------------------------------------
  1       (*S*)-**6**\   ICH~2~CF~3~ (1.05 eq. 29.32 g), KOH (96.8% assay, 1.05 eq. 8.14 g),\    (*S*)(2*S*)-**7**\
          80 g           MeOH (0.9 v, 72 mL), DMF (10 v, 800 mL), rt (room temperature), 1 h     73.7 g, 81.1% yield, \>99% de (diasteromeric excess)

  2       (*S*)-**6**\   ICH~2~CF~3~ (1.05 eq. 91.61 g), KOH (96.8% assay, 1.05 eq. 25.42 g),\   (*S*)(2*S*)-**7**\
          250 g          MeOH (0.9 v, 225 mL), DMF (10 v, 2500 mL), rt, 1 h                      229.1 g, 80.7% yield, 99.9% de

  3       (*S*)-**6**\   ICH~2~CF~3~ (1.05 eq. 91.61 g), KOH (96.8% assay, 1.05 eq. 25.42 g),\   (*S*)(2*S*)-**7**\
          250 g          MeOH (0.9 v, 225 mL), DMF (10 v, 2500 mL), rt, 1 h                      228.5 g, 80.4% yield, \>99% de
  -----------------------------------------------------------------------------------------------------------------------------------------------------

molecules-24-04521-t002_Table 2

###### 

Optimized conditions for preparation of Fmoc derivative (*S*)-**12** and reproducibility of the method.

  --------------------------------------------------------------------------------------------------------------------------------------------
  Entry   (*S*)(2*S*)-7   Conditions                                                      (*S*)-12
  ------- --------------- --------------------------------------------------------------- ----------------------------------------------------
  1       10 g            6N HCl (5 eq. 12.2 mL), DME (2 v, 20 mL), 50 °C, 1 h\           4.26 g, 76.7% yield 99.0% ee (enantiomeric excess)
                          added H~2~O (2 v, 20 mL), 30 °C, 2 h\                           
                          then EDTA•2Na (1.02 eq. 5.55 g), 48% NaOH (4.2 eq. 5.1 g)\      
                          Na~2~CO~3~ (1.3 eq. 2.02 g), Fmoc-OSu (1 eq. 4.94 g)\           
                          MeCN (4 v, 9.2 mL), rt, 3 h                                     

  2       220 g           6N HCl (5 eq. 268 mL), DME (2 v, 440 mL), 50 °C, 1 h\           92.7 g, 75.9% yield 98.8% ee
                          added H~2~O (2 v, 440 mL), 30 °C, 2 h\                          
                          then EDTA•2Na (1.02 eq. 122.2 g), 48% NaOH (5.4 eq. 143.6 g)\   
                          Na~2~CO~3~ (1.3 eq. 44.35 g), Fmoc-OSu (1 eq. 108.57 g)\        
                          MeCN (4 v, 200 mL), rt, 4 h                                     

  3       220 g           6N HCl (5 eq. 268 mL), DME (2 v, 440 mL), 50 °C, 1 h\           99.5 g, 81.5% yield 98.4% ee
                          added H~2~O (2 v, 440 mL), 30 °C, 1.5 h\                        
                          then EDTA•2Na (1.02 eq. 122.2 g), 48% NaOH (5.2 eq. 138 g)\     
                          Na~2~CO~3~ (1.3 eq. 44.35 g), Fmoc-OSu (1 eq. 108.57 g)\        
                          MeCN (4 v, 200 mL), rt, 4 h                                     
  --------------------------------------------------------------------------------------------------------------------------------------------
